These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

969 related articles for article (PubMed ID: 27882473)

  • 1. Foxp3, Regulatory T Cell, and Autoimmune Diseases.
    Tao JH; Cheng M; Tang JP; Liu Q; Pan F; Li XP
    Inflammation; 2017 Feb; 40(1):328-339. PubMed ID: 27882473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of FOXP3
    Mohr A; Atif M; Balderas R; Gorochov G; Miyara M
    Clin Exp Immunol; 2019 Jul; 197(1):24-35. PubMed ID: 30830965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CD4+CD25high regulatory T-cells and FoxP3 expression in the peripheral blood of patients with systemic lupus erythematosus.
    Atfy M; Amr GE; Elnaggar AM; Labib HA; Esh A; Elokely AM
    Egypt J Immunol; 2009; 16(1):117-26. PubMed ID: 20726328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations.
    Ge J; Yin X; Chen L
    Front Immunol; 2024; 15():1457189. PubMed ID: 39290699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Progression Locus 2 (Tpl2) Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Inhibits Forkhead Box P3 (FoxP3) Expression, and Limits Regulatory T Cell (Treg) Immunosuppressive Functions.
    Li X; Acuff NV; Peeks AR; Kirkland R; Wyatt KD; Nagy T; Watford WT
    J Biol Chem; 2016 Aug; 291(32):16802-15. PubMed ID: 27261457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4(+)FoxP3(+) regulatory T-cells in human systemic lupus erythematosus.
    Suen JL; Chiang BL
    J Formos Med Assoc; 2012 Sep; 111(9):465-70. PubMed ID: 23021502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases.
    Shu Y; Hu Q; Long H; Chang C; Lu Q; Xiao R
    Clin Rev Allergy Immunol; 2017 Apr; 52(2):260-272. PubMed ID: 27687891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
    Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
    J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imbalance of regulatory T cells in human autoimmune diseases.
    Dejaco C; Duftner C; Grubeck-Loebenstein B; Schirmer M
    Immunology; 2006 Mar; 117(3):289-300. PubMed ID: 16476048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cell metabolism at the intersection between autoimmune diseases and cancer.
    Kurniawan H; Soriano-Baguet L; Brenner D
    Eur J Immunol; 2020 Nov; 50(11):1626-1642. PubMed ID: 33067808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases.
    Sharabi A; Mozes E
    Immunotherapy; 2009 May; 1(3):385-401. PubMed ID: 20635958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR signaling, Tregs and immune modulation.
    Chapman NM; Chi H
    Immunotherapy; 2014; 6(12):1295-311. PubMed ID: 25524385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp
    Ferreira RC; Castro Dopico X; Oliveira JJ; Rainbow DB; Yang JH; Trzupek D; Todd SA; McNeill M; Steri M; Orrù V; Fiorillo E; Crouch DJM; Pekalski ML; Cucca F; Tree TI; Vyse TJ; Wicker LS; Todd JA
    Front Immunol; 2019; 10():2606. PubMed ID: 31781109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T cells in systemic lupus erythematosus.
    Ohl K; Tenbrock K
    Eur J Immunol; 2015 Feb; 45(2):344-55. PubMed ID: 25378177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forkhead box protein 3: essential immune regulatory role.
    Nik Tavakoli N; Hambly BD; Sullivan DR; Bao S
    Int J Biochem Cell Biol; 2008; 40(11):2369-73. PubMed ID: 18037337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis.
    Miao J; Zhu P
    Curr Rheumatol Rep; 2018 Apr; 20(5):30. PubMed ID: 29663162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance.
    Dummer CD; Carpio VN; Gonçalves LF; Manfro RC; Veronese FV
    Transpl Immunol; 2012 Jan; 26(1):1-10. PubMed ID: 21939765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.
    Sakaguchi S; Ono M; Setoguchi R; Yagi H; Hori S; Fehervari Z; Shimizu J; Takahashi T; Nomura T
    Immunol Rev; 2006 Aug; 212():8-27. PubMed ID: 16903903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns.
    Miyara M; Sakaguchi S
    Immunol Cell Biol; 2011 Mar; 89(3):346-51. PubMed ID: 21301480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.